Research graph
References from Clinical and Biological Factors Associated with Pseudoprogression Under Immune Checkpoint Inhibitors: A Retrospective Pan-Tumor Cohort Study. Local targets link to admitted publications; unresolved targets remain external evidence.
Improved Survival with Ipilimumab in patients with metastatic melanoma
10.1056/nejmoa1003466 · 2010 · External reference
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
10.1056/nejmoa1510665 · 2015 · External reference
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study
10.1016/s1470-2045(17)30616-2 · 2017 · External reference
Tumor microenvironment and therapeutic response
10.1016/j.canlet.2016.01.043 · 2017 · External reference
Hallmarks of Cancer: New Dimensions
10.1158/2159-8290.cd-21-1059 · 2022 · External reference
A systematic review and network meta analysis of first-line immunotherapy for advanced urothelial carcinoma
2026 · External reference
Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: An update
2025 · External reference
MicroRNAs as key regulators of cancer drug resistance: Insights and future directions in chemotherapy, targeted-therapy, radiotherapy, and immunotherapy
2025 · External reference
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: Clinical and immunological evidence from three patient cases
10.1007/s00262-008-0642-y · 2009 · External reference
Pseudoprogression and Immune-Related Response in Solid Tumors
10.1200/jco.2015.61.6870 · 2015 · External reference
Immune-related tumour response assessment criteria: A comprehensive review
10.1259/bjr.20170457 · 2018 · External reference
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
10.1158/1078-0432.ccr-09-1624 · 2009 · External reference
Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy
10.1007/s40259-020-00425-y · 2020 · External reference
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
10.1016/j.ejca.2008.10.026 · 2009 · External reference
iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics
10.1016/s1470-2045(17)30074-8 · 2017 · External reference
Radiologische Responsebeurteilung moderner Immuntherapien mithilfe von iRECIST
10.1007/s00117-017-0289-9 · 2017 · External reference
10.1002/0471722146
10.1002/0471722146 · External reference
Unresolved reference
External reference
10.1186/1471-2105-12-77
10.1186/1471-2105-12-77 · External reference
ROCR: Visualizing classifier performance in R
10.1093/bioinformatics/bti623 · 2005 · External reference
10.32614/cran.package.crosstable
10.32614/cran.package.crosstable · External reference
Pseudoprogression in lung cancer patients treated with immunotherapy
10.1016/j.critrevonc.2021.103531 · 2022 · External reference
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025
10.1016/j.eururo.2017.03.037 · 2017 · External reference
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients with Advanced Melanoma Treated with Pembrolizumab
10.1200/jco.2015.64.0391 · 2016 · External reference
Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions
10.1158/1078-0432.ccr-17-0114 · 2017 · External reference
Response to PD1 inhibition in conventional chondrosarcoma
10.1186/s40425-018-0413-z · 2018 · External reference
Pseudoprogression and hyperprogression after checkpoint blockade
10.1016/j.intimp.2018.03.018 · 2018 · External reference
Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: A case report and literature review
10.18632/oncotarget.18361 · 2017 · External reference
Hyperprogressive disease: Recognizing a novel pattern to improve patient management
10.1038/s41571-018-0111-2 · 2018 · External reference
10.3389/fmed.2020.00366
10.3389/fmed.2020.00366 · External reference
10.3390/cancers11111699
10.3390/cancers11111699 · External reference
Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition
10.1158/1078-0432.ccr-20-0020 · 2020 · External reference
10.3389/fonc.2021.689802
10.3389/fonc.2021.689802 · External reference
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: An imaging biomarker, retrospective multicohort study
10.1016/s1470-2045(18)30413-3 · 2018 · External reference
10.3390/cancers14020350
10.3390/cancers14020350 · External reference
Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting
10.1080/2162402x.2022.2052410 · 2022 · External reference
Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma
10.18632/oncotarget.16935 · 2017 · External reference
Association Between Circulating Tumor DNA and Pseudoprogression in Patients with Metastatic Melanoma Treated with Anti–Programmed Cell Death 1 Antibodies
10.1001/jamaoncol.2017.5332 · 2018 · External reference
Association Between Circulating Tumor DNA and Pseudoprogression in Patients with Metastatic Melanoma Treated with Anti–Programmed Cell Death 1 Antibodies
10.1001/jamaoncol.2017.5332 · ExternalCitation · doi-reference
10.1002/0471722146
10.1002/0471722146 · ExternalCitation · doi-reference
Radiologische Responsebeurteilung moderner Immuntherapien mithilfe von iRECIST
10.1007/s00117-017-0289-9 · ExternalCitation · doi-reference
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: Clinical and immunological evidence from three patient cases
10.1007/s00262-008-0642-y · ExternalCitation · doi-reference
Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy
10.1007/s40259-020-00425-y · ExternalCitation · doi-reference
Tumor microenvironment and therapeutic response
10.1016/j.canlet.2016.01.043 · ExternalCitation · doi-reference
Pseudoprogression in lung cancer patients treated with immunotherapy
10.1016/j.critrevonc.2021.103531 · ExternalCitation · doi-reference
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
10.1016/j.ejca.2008.10.026 · ExternalCitation · doi-reference
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025
10.1016/j.eururo.2017.03.037 · ExternalCitation · doi-reference
Pseudoprogression and hyperprogression after checkpoint blockade
10.1016/j.intimp.2018.03.018 · ExternalCitation · doi-reference
iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics
10.1016/s1470-2045(17)30074-8 · ExternalCitation · doi-reference
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study
10.1016/s1470-2045(17)30616-2 · ExternalCitation · doi-reference
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: An imaging biomarker, retrospective multicohort study
10.1016/s1470-2045(18)30413-3 · ExternalCitation · doi-reference
Hyperprogressive disease: Recognizing a novel pattern to improve patient management
10.1038/s41571-018-0111-2 · ExternalCitation · doi-reference
Improved Survival with Ipilimumab in patients with metastatic melanoma
10.1056/nejmoa1003466 · ExternalCitation · doi-reference
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
10.1056/nejmoa1510665 · ExternalCitation · doi-reference
Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting
10.1080/2162402x.2022.2052410 · ExternalCitation · doi-reference
ROCR: Visualizing classifier performance in R
10.1093/bioinformatics/bti623 · ExternalCitation · doi-reference
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
10.1158/1078-0432.ccr-09-1624 · ExternalCitation · doi-reference
Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions
10.1158/1078-0432.ccr-17-0114 · ExternalCitation · doi-reference
Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition
10.1158/1078-0432.ccr-20-0020 · ExternalCitation · doi-reference
Hallmarks of Cancer: New Dimensions
10.1158/2159-8290.cd-21-1059 · ExternalCitation · doi-reference
10.1186/1471-2105-12-77
10.1186/1471-2105-12-77 · ExternalCitation · doi-reference
Response to PD1 inhibition in conventional chondrosarcoma
10.1186/s40425-018-0413-z · ExternalCitation · doi-reference
Pseudoprogression and Immune-Related Response in Solid Tumors
10.1200/jco.2015.61.6870 · ExternalCitation · doi-reference
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients with Advanced Melanoma Treated with Pembrolizumab
10.1200/jco.2015.64.0391 · ExternalCitation · doi-reference
Immune-related tumour response assessment criteria: A comprehensive review
10.1259/bjr.20170457 · ExternalCitation · doi-reference
Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma
10.18632/oncotarget.16935 · ExternalCitation · doi-reference
Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: A case report and literature review
10.18632/oncotarget.18361 · ExternalCitation · doi-reference
10.32614/cran.package.crosstable
10.32614/cran.package.crosstable · ExternalCitation · doi-reference
10.3389/fmed.2020.00366
10.3389/fmed.2020.00366 · ExternalCitation · doi-reference
10.3389/fonc.2021.689802
10.3389/fonc.2021.689802 · ExternalCitation · doi-reference
10.3390/cancers11111699
10.3390/cancers11111699 · ExternalCitation · doi-reference
10.3390/cancers14020350
10.3390/cancers14020350 · ExternalCitation · doi-reference
